2020 Q2 Form 10-Q Financial Statement

#000135657620000054 Filed on August 17, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $126.7M $104.7M
YoY Change 21.05% 5.18%
Cost Of Revenue $8.386M $4.044M
YoY Change 107.37% 9.8%
Gross Profit $118.3M $100.7M
YoY Change 17.58% 5.0%
Gross Profit Margin 93.38% 96.14%
Selling, General & Admin $48.10M $39.78M
YoY Change 20.93% -0.8%
% of Gross Profit 40.65% 39.52%
Research & Development $22.25M $16.97M
YoY Change 31.1% -15.31%
% of Gross Profit 18.8% 16.86%
Depreciation & Amortization $3.300M $1.700M
YoY Change 94.12% -5.56%
% of Gross Profit 2.79% 1.69%
Operating Expenses $70.35M $56.75M
YoY Change 23.97% -5.63%
Operating Profit $45.55M $42.60M
YoY Change 6.93% 19.26%
Interest Expense $5.815M $5.389M
YoY Change 7.9% -869.86%
% of Operating Profit 12.77% 12.65%
Other Income/Expense, Net $1.662M $148.0K
YoY Change 1022.97% -107.94%
Pretax Income $47.21M $42.75M
YoY Change 10.44% 26.26%
Income Tax $12.54M $10.02M
% Of Pretax Income 26.57% 23.44%
Net Earnings $34.67M $32.73M
YoY Change 5.93% 6.47%
Net Earnings / Revenue 27.36% 31.26%
Basic Earnings Per Share $0.66 $0.62
Diluted Earnings Per Share $0.65 $0.61
COMMON SHARES
Basic Shares Outstanding 52.56M shares 52.39M shares
Diluted Shares Outstanding 53.65M shares 53.91M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $374.8M $258.6M
YoY Change 44.93% 48.28%
Cash & Equivalents $211.0M $87.34M
Short-Term Investments $163.8M $171.2M
Other Short-Term Assets $20.40M $21.80M
YoY Change -6.42% 49.32%
Inventory $35.34M $26.02M
Prepaid Expenses
Receivables $126.6M $84.56M
Other Receivables $0.00 $0.00
Total Short-Term Assets $557.2M $390.9M
YoY Change 42.53% 37.4%
LONG-TERM ASSETS
Property, Plant & Equipment $17.94M $4.028M
YoY Change 345.41% -17.8%
Goodwill $88.10M
YoY Change
Intangibles $408.3M $28.79M
YoY Change 1318.25%
Long-Term Investments $358.7M $593.8M
YoY Change -39.59% 17.98%
Other Assets $17.12M $581.0K
YoY Change 2846.3% -97.79%
Total Long-Term Assets $933.9M $672.8M
YoY Change 38.81% 18.38%
TOTAL ASSETS
Total Short-Term Assets $557.2M $390.9M
Total Long-Term Assets $933.9M $672.8M
Total Assets $1.491B $1.064B
YoY Change 40.18% 24.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.515M $4.081M
YoY Change 35.14% 40.72%
Accrued Expenses $206.5M $134.5M
YoY Change 53.53% 35.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.200M
YoY Change
Total Short-Term Liabilities $269.3M $144.0M
YoY Change 87.03% 38.57%
LONG-TERM LIABILITIES
Long-Term Debt $371.7M $337.2M
YoY Change 10.23% 4.75%
Other Long-Term Liabilities $9.560M $10.96M
YoY Change -12.73% -69.99%
Total Long-Term Liabilities $9.560M $10.96M
YoY Change -12.73% -96.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $269.3M $144.0M
Total Long-Term Liabilities $9.560M $10.96M
Total Liabilities $825.0M $540.8M
YoY Change 52.57% 16.97%
SHAREHOLDERS EQUITY
Retained Earnings $255.7M $137.6M
YoY Change 85.91%
Common Stock $53.00K $52.00K
YoY Change 1.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $666.0M $522.9M
YoY Change
Total Liabilities & Shareholders Equity $1.491B $1.064B
YoY Change 40.18% 24.73%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income $34.67M $32.73M
YoY Change 5.93% 6.47%
Depreciation, Depletion And Amortization $3.300M $1.700M
YoY Change 94.12% -5.56%
Cash From Operating Activities $92.00M $28.70M
YoY Change 220.56% 334.85%
INVESTING ACTIVITIES
Capital Expenditures -$600.0K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$107.7M -$65.80M
YoY Change 63.68% -84.4%
Cash From Investing Activities -$108.1M -$65.80M
YoY Change 64.29% -84.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.500M 1.600M
YoY Change -6.25% -76.12%
NET CHANGE
Cash From Operating Activities 92.00M 28.70M
Cash From Investing Activities -108.1M -65.80M
Cash From Financing Activities 1.500M 1.600M
Net Change In Cash -14.60M -35.50M
YoY Change -58.87% -91.32%
FREE CASH FLOW
Cash From Operating Activities $92.00M $28.70M
Capital Expenditures -$600.0K $0.00
Free Cash Flow $92.60M $28.70M
YoY Change 222.65% 315.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001356576
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35518
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-2590184
dei Entity Address Address Line1
EntityAddressAddressLine1
9715 Key West Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
dei Entity Registrant Name
EntityRegistrantName
SUPERNUS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
838-2500
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52664084 shares
dei Trading Symbol
TradingSymbol
SUPN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
210975000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
181381000 USD
CY2020Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
163839000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
165692000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
126559000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
87332000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
35338000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
26628000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20442000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11611000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
557153000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
472644000 USD
CY2020Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
358673000 USD
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
591773000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17941000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17068000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21289000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21279000 USD
CY2020Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
22479000 USD
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0 USD
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
408272000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24840000 USD
CY2020Q2 us-gaap Goodwill
Goodwill
88095000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
0 USD
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
32063000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17118000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
615000 USD
CY2020Q2 us-gaap Assets
Assets
1491020000 USD
CY2019Q4 us-gaap Assets
Assets
1160282000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5515000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10141000 USD
CY2020Q2 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
144105000 USD
CY2019Q4 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
107629000 USD
CY2020Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
58818000 USD
CY2019Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
34305000 USD
CY2020Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
23500000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 USD
CY2020Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
25052000 USD
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2443000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3560000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2825000 USD
CY2020Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
4201000 USD
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0 USD
CY2020Q2 supn Non Recourse Debt Sale Of Future Royalties Current
NonRecourseDebtSaleOfFutureRoyaltiesCurrent
4525000 USD
CY2019Q4 supn Non Recourse Debt Sale Of Future Royalties Current
NonRecourseDebtSaleOfFutureRoyaltiesCurrent
3244000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
269276000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
160587000 USD
CY2020Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
353349000 USD
CY2019Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
345170000 USD
CY2020Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
92200000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0 USD
CY2020Q2 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
16455000 USD
CY2019Q4 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
19248000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30108000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30440000 USD
CY2020Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
18382000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0 USD
CY2020Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
35716000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9560000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9409000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
825046000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
564854000 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52624084 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52624084 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52533348 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52533348 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
53000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
53000 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
398829000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
388410000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11359000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7417000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
255733000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
199548000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
665974000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
595428000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1491020000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1160282000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
126729000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
104695000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
221705000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
190169000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8386000 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4044000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12538000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7728000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22247000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
42598000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16970000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41184000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32364000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
48103000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39777000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
89717000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
79439000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2445000 USD
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1306000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3706000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2612000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
81181000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
62097000 USD
us-gaap Costs And Expenses
CostsAndExpenses
147145000 USD
us-gaap Costs And Expenses
CostsAndExpenses
122143000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
45548000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
74560000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
68026000 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4151000 USD
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5448000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
9726000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
10137000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
5815000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
5389000 USD
us-gaap Interest Expense
InterestExpense
11570000 USD
us-gaap Interest Expense
InterestExpense
11268000 USD
CY2020Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3326000 USD
CY2019Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
89000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3528000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
90000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1662000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
148000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1684000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.98
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1041000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
47210000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
42746000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
76244000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
66985000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12543000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10019000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20059000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15918000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
34667000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
32727000 USD
us-gaap Net Income Loss
NetIncomeLoss
56185000 USD
us-gaap Net Income Loss
NetIncomeLoss
51067000 USD
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.66
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.07
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.65
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.95
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52557035 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52385590 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52545910 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52361149 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53645828 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53912977 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53611418 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53947834 shares
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
34667000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
32727000 USD
us-gaap Net Income Loss
NetIncomeLoss
56185000 USD
us-gaap Net Income Loss
NetIncomeLoss
51067000 USD
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
11525000 USD
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4497000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
3942000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
9082000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11525000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4497000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3942000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9082000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
46192000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
37224000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
60127000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
60149000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
595428000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3988000 USD
CY2020Q1 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
32000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
21518000 USD
CY2020Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-7583000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
613383000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4962000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
981000 USD
CY2020Q2 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
456000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
34667000 USD
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
11525000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
665974000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
453023000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3287000 USD
CY2019Q1 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
783000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
18340000 USD
CY2019Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4585000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
480018000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4022000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1377000 USD
CY2019Q2 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
263000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
32727000 USD
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4497000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
522904000 USD
us-gaap Profit Loss
ProfitLoss
56185000 USD
us-gaap Profit Loss
ProfitLoss
51067000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8950000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
7309000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5044000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3355000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-984000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1625000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8179000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
7748000 USD
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
3316000 USD
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
93000 USD
supn Interest Expense Non Recourse Royalty Liability
InterestExpenseNonRecourseRoyaltyLiability
2870000 USD
supn Interest Expense Non Recourse Royalty Liability
InterestExpenseNonRecourseRoyaltyLiability
2851000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
3918000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
3368000 USD
supn Noncash Operating Lease Cost
NoncashOperatingLeaseCost
1842000 USD
supn Noncash Operating Lease Cost
NoncashOperatingLeaseCost
1230000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3062000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
861000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
20431000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-18439000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1689000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
365000 USD
supn Increase Decrease In Prepaid Deferred Expense And Other Current Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets
4767000 USD
supn Increase Decrease In Prepaid Deferred Expense And Other Current Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets
3581000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1176000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
140000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7199000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
886000 USD
supn Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
28298000 USD
supn Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
-11129000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
10913000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1307000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
22513000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-9703000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2731000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-755000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
100867000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
61680000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
297200000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
15000000 USD
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
15382000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
264926000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
257936000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
96165000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3072000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
245000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
24000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72742000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-169007000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1469000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2423000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1469000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2423000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29594000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-104904000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181381000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192248000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
210975000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87344000 USD
us-gaap Interest Paid Net
InterestPaidNet
1258000 USD
us-gaap Interest Paid Net
InterestPaidNet
1258000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
607000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
24795000 USD
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
115700000 USD
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
0 USD
supn Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
365000 USD
supn Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
280000 USD
supn Property And Equipment Acquired Under Build To Suit Lease Transaction
PropertyAndEquipmentAcquiredUnderBuildToSuitLeaseTransaction
0 USD
supn Property And Equipment Acquired Under Build To Suit Lease Transaction
PropertyAndEquipmentAcquiredUnderBuildToSuitLeaseTransaction
431000 USD
supn Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
24738000 USD
supn Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
31727000 USD
us-gaap Nature Of Operations
NatureOfOperations
Organization and Business<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supernus Pharmaceuticals, Inc. (the Company) was incorporated in Delaware, commencing operations in 2005. The Company is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, marketing five products: Oxtellar XR for the treatment of epilepsy; Trokendi XR for the prophylaxis of migraine headache and the treatment of epilepsy; APOKYN and XADAGO for the treatment of Parkinson's disease and MYOBLOC for the treatment of cervical dystonia and sialorrhea. The Company is also developing multiple proprietary CNS product candidates to address significant unmet medical needs and market opportunities.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company launched Oxtellar XR and Trokendi XR for the treatment of epilepsy in 2013, followed by the launch of Trokendi XR for the prophylaxis of migraine headache in adolescents and adults in 2017. The Company launched Oxtellar XR with an expanded indication to include monotherapy for partial seizures in January 2019. On June 9, 2020, the Company completed the previously announced acquisition of the CNS portfolio of US WorldMeds Partners, LLC (USWM Acquisition). With the acquisition, the Company acquired the right to further develop and commercialize three marketed products and a product candidate in late-stage development. Refer to Note 3 for further discussion on the USWM Acquisition. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">COVID-19 Impact</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business operations, and has assessed the impact of the COVID-19 pandemic on its condensed consolidated financial statements as of June 30, 2020. Through the first six months of 2020, the impact of the pandemic has had limited effect on the Company's business operations, and no material impact on its condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the situation surrounding the COVID-19 pandemic remains fluid and the duration is uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.</span></div>
supn Number Of Proprietary Commercial Products
NumberOfProprietaryCommercialProducts
5 numberOfMarketProducts
supn Sales Return Period
SalesReturnPeriod
P12M
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Reclassifications</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain prior year amounts on the condensed consolidated statements of earnings have been reclassified to conform to the current year presentation, including a reclassification made to separately present amortization of intangible assets, previously included in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, general and administrative expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization of intangible assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> on the condensed consolidated statements of earnings. These reclassifications had no effect on operating earnings or our other condensed consolidated financial statements for the three and six months ended June 30, 2020 and 2019.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company evaluates the methodologies employed in making its estimates on an ongoing basis.</span></div>
supn Sales Return Period Prior To Expiration
SalesReturnPeriodPriorToExpiration
P6M
supn Number Of Proprietary Commercial Products
NumberOfProprietaryCommercialProducts
5 product
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2020Q2 supn Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Finance Lease Liability
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiability
22747000 USD
supn Business Acquisition Transaction Costs Adjustment
BusinessAcquisitionTransactionCostsAdjustment
10100000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
126729000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
104695000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
221705000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
190169000 USD
CY2020Q2 supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
2300000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
3900000 USD
CY2019Q2 supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
1800000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
3400000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
507375000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
747598000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15525000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10031000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
388000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
164000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
522512000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
757465000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
163839000 USD
CY2020Q2 supn Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
143987000 USD
CY2020Q2 supn Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue
149688000 USD
CY2020Q2 supn Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue
64998000 USD
CY2020Q2 supn Available For Sale Securities Debt Maturities Thereafter Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue
0 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
522512000 USD
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4962000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4022000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8950000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7309000 USD
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
34667000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
32727000 USD
us-gaap Net Income Loss
NetIncomeLoss
56185000 USD
us-gaap Net Income Loss
NetIncomeLoss
51067000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52557035 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52385590 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52545910 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52361149 shares
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1088793 shares
CY2019Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1527387 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1065508 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1586685 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53645828 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53912977 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53611418 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53947834 shares
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.66
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.98
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.65
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.95
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12543000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10019000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20059000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15918000 USD
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.266
CY2019Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.234
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.263
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
17418000 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.238
CY2020Q2 supn Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
12400000 USD
CY2019Q4 supn Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
11000000.0 USD
CY2020Q2 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
7262000 USD
CY2019Q4 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
4582000 USD
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
10658000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
11428000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10618000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
35338000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
26628000 USD
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31740000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29767000 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13799000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12699000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17941000 USD
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17068000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000 USD
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000 USD
CY2020Q2 us-gaap Goodwill Gross
GoodwillGross
88095000 USD
CY2019Q4 us-gaap Goodwill Gross
GoodwillGross
0 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
22242000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
18535000 USD
CY2020Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
408272000 USD
CY2019Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
24840000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3700000 USD
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2600000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5861000 USD
CY2020Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
58818000 USD
CY2019Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
34305000 USD
CY2020Q2 supn Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
10735000 USD
CY2019Q4 supn Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
13285000 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11995000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11223000 USD
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
10090000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3936000 USD
CY2020Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
12957000 USD
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13041000 USD
CY2020Q2 supn Accrued Rebates
AccruedRebates
118335000 USD
CY2019Q4 supn Accrued Rebates
AccruedRebates
88811000 USD
CY2020Q2 supn Accrued Product Returns
AccruedProductReturns
25770000 USD
CY2019Q4 supn Accrued Product Returns
AccruedProductReturns
18818000 USD
CY2020Q2 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
144105000 USD
CY2019Q4 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
107629000 USD
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4792000 USD
CY2019Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4253000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
9485000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
8972000 USD
CY2020Q2 us-gaap Interest Expense Other
InterestExpenseOther
1023000 USD
CY2019Q2 us-gaap Interest Expense Other
InterestExpenseOther
1136000 USD
us-gaap Interest Expense Other
InterestExpenseOther
2085000 USD
us-gaap Interest Expense Other
InterestExpenseOther
2296000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
5815000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
5389000 USD
us-gaap Interest Expense
InterestExpense
11570000 USD
us-gaap Interest Expense
InterestExpense
11268000 USD
CY2020Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4200000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8200000 USD
CY2019Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3900000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
7700000 USD
CY2014Q3 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
30000000.0 USD

Files In Submission

Name View Source Status
0001356576-20-000054-index-headers.html Edgar Link pending
0001356576-20-000054-index.html Edgar Link pending
0001356576-20-000054.txt Edgar Link pending
0001356576-20-000054-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
supn-20200630.htm Edgar Link pending
supn-20200630.xsd Edgar Link pending
supn-20200630x10qxex101.htm Edgar Link pending
supn-20200630x10qxex102.htm Edgar Link pending
supn-20200630x10qxex103.htm Edgar Link pending
supn-20200630x10qxex104.htm Edgar Link pending
supn-20200630x10qxex105.htm Edgar Link pending
supn-20200630x10qxex311.htm Edgar Link pending
supn-20200630x10qxex312.htm Edgar Link pending
supn-20200630x10qxex321.htm Edgar Link pending
supn-20200630x10qxex322.htm Edgar Link pending
supn-20200630x10xqxex21.htm Edgar Link pending
supn-20200630_cal.xml Edgar Link unprocessable
supn-20200630_def.xml Edgar Link unprocessable
supn-20200630_g1.jpg Edgar Link pending
supn-20200630_htm.xml Edgar Link completed
supn-20200630_lab.xml Edgar Link unprocessable
supn-20200630_pre.xml Edgar Link unprocessable